Asherman_Syndrome

1. Disease Information

Overview. Asherman syndrome is a rare, acquired gynecological disorder characterized by the formation of intrauterine adhesions (IUA) / synechiae — fibrous scar tissue that partially or completely obliterates the uterine cavity and/or cervical canal. It arises from damage to the basal (regenerative) layer of the endometrium, most often after intrauterine instrumentation, leading to non-regenerative healing in which functional endometrium is replaced by fibrous connective tissue and opposing uterine walls adhere. The clinical triad is menstrual abnormality (hypomenorrhea/amenorrhea), infertility/recurrent pregnancy loss, and cyclic pelvic pain. The eponym honors Joseph Asherman, who characterized the syndrome in 1948–1950.

A useful nomenclature distinction (increasingly emphasized in the literature): "intrauterine adhesions" is the anatomical/hysteroscopic finding, whereas "Asherman syndrome" is reserved for IUA accompanied by symptoms (menstrual disturbance, infertility, pain). In one retrospective cohort, of patients with adhesions, 76.1% were classified as IUA and 23.9% met criteria for symptomatic Asherman syndrome (PMID:40310333).

Key identifiers: - MONDO: MONDO:0015299 - Orphanet: ORPHA:137686 - ICD-10: N85.6 (Intrauterine synechiae) - ICD-11: GA20 (Non-inflammatory disorders of the uterus) / relevant synechiae code - MeSH: "Gynatresia" / "Asherman Syndrome" is indexed under MeSH term D054882 (Gynatresia); IUA also indexed under uterine diseases - OMIM: Not applicable (acquired, non-Mendelian) - NORD: Listed rare disease profile (NORD)

Synonyms / alternative names: Intrauterine adhesions; intrauterine synechiae; uterine synechiae; endometrial sclerosis; sclerotic endometrium; traumatic uterine atrophy; uterine/cervical atresia (older usage); Asherman's syndrome. (NORD, Orphanet)

Data derivation: Disease-level knowledge is aggregated from case series, retrospective cohorts, hysteroscopy registries, and increasingly from single-cell molecular atlases of patient endometrium — not from a single population EHR resource. It is under-captured in administrative datasets because many cases are diagnosed only at hysteroscopy during infertility work-up.

2. Etiology

Primary causal mechanism — endometrial basalis trauma. The dominant cause (>90% of cases) is iatrogenic mechanical injury to the endometrial basal layer, typically in a hormonally hypoestrogenic, recently pregnant uterus where the endometrium is thin and vulnerable (PMID:40310333).

Disease causal factors / procedures: - Dilation and curettage (D&C) for miscarriage or retained products of conception (RPOC) — the single most common cause; up to ~40% of women undergoing D&C for RPOC develop adhesions (management review, Springer). - Postpartum curettage — IUA in ~22% (PMID:40310333). - Termination of pregnancy (TOP) — first-trimester ~21.2%; second-trimester 16.2–21% (PMID:40310333). - Myomectomy — ~9.3% incidence, especially with cavity entry (PMID:40310333). - Cesarean section, B-Lynch compression suturing, uterine artery embolization, and other conservative postpartum-hemorrhage interventions. - Infectious / inflammatory causes: genital tuberculosis (a leading cause in endemic regions, often producing severe disease), schistosomiasis, chronic endometritis, and pelvic inflammatory disease. - Congenital predisposition: Müllerian anomalies — one series found 31.6% of septate uteri developed IUAs (PMID:40310333).

Risk factors (environmental / clinical): - Timing of curettage is the most consistent modifiable risk factor: all women who developed IUA in one post-abortion cohort had undergone curettage 8–28 days after delivery/miscarriage, with 75% in the 14–24-day window (Identifying risk factors and incidence, PMID:33462894). Elevated risk persists up to ~4 weeks post-delivery/miscarriage. - Repeated uterine instrumentation / repeat abortions — the principal risk factor; risk rises with number of procedures. - Negative uterine (suction) pressure — extremely strong association (OR 125.61, 95% CI 67.35–183.87) (PMID:40310333). - Chronic endometritis — present in 64.3% of severe cases (PMID:40310333). - Age >35 years (confounded by cumulative prior procedures); low estrogen state.

Genetic risk factors: None established as causal. AS is acquired. There may be individual variation in fibrotic/wound-healing propensity (e.g., TGF-β pathway polymorphisms), but no validated susceptibility locus, GWAS signal, or ClinVar entry exists for AS. Not Applicable / Not established.

Protective factors: The strongest protective strategy is avoiding sharp curettage in favor of medical management (misoprostol) or ultrasound-guided gentle suction/manual vacuum aspiration, and avoiding the high-risk 2–4 week postpartum window (Fertility & Sterility, uterine evacuation approach). No genetic protective variants are known.

Gene–environment interactions: Not characterized for AS. Host fibrotic response to endometrial injury is the plausible interaction axis but is unproven.

3. Phenotypes

Characteristics: - Age of onset: Reproductive-age adult; onset is temporally linked to the inciting procedure (mean age ~33 years in cohorts; onset days-to-weeks after instrumentation) (PMID:40310333). - Severity: Variable — graded mild/moderate/severe. AS cohorts skew severe (58.1% AFS stage III) vs IUA cohorts skewing mild (54.9% AFS stage I) (PMID:40310333). - Progression: Chronic and, without treatment, stable-to-progressive; adhesions can re-form aggressively after lysis (severe cases up to 62.5% recurrence, see §11). - QoL impact: Substantial — infertility, pregnancy loss, chronic cyclic pain, and psychological distress; measured with general instruments (SF-36/EQ-5D) rather than AS-specific tools.

4. Genetic / Molecular Information

Causal genes: None. Asherman syndrome is an acquired fibrotic disorder with no Mendelian gene, no pathogenic germline variant, and no OMIM entry. ClinVar/HGMD/COSMIC are Not Applicable.

Molecularly dysregulated genes (acquired expression changes, not mutations) — from single-cell and expression studies: - TGFB1 (TGF-β1) — up-regulated; central pro-fibrotic driver via SMAD2/3 signaling, promoting myofibroblast differentiation (single-cell review searches). - ACTA2 (α-SMA) and COL1A1 (collagen I) — up-regulated myofibroblast/ECM markers. - THBS1 (thrombospondin-1) — identified as a key pro-fibrotic factor modulating PI3K/AKT, and a stem-cell-reversible target (Frontiers, THBS1). - SLPI (secretory leukocyte protease inhibitor) — marks a stressed epithelial subpopulation characteristic of AS during the implantation window (Nat Commun single-cell atlas, PMID:37735465). - WNT7A / FZD6 / LRP6 — loss of ligand–receptor communication (impaired epithelial differentiation). - JAG1 / NOTCH2 — decreased communication affecting glandular differentiation. - IGFBP3/5/6 — up-regulated anti-angiogenic factors. - Stress-response genes HSPA1A, SOCS3 co-expressed in the stressed epithelium.

Suggested HGNC/gene annotations: TGFB1 (hgnc:11766), ACTA2 (hgnc:130), COL1A1 (hgnc:2197), THBS1 (hgnc:11785), SLPI (hgnc:11092), WNT7A (hgnc:12786), NOTCH2 (hgnc:7882).

Epigenetics: Emerging evidence implicates altered DNA methylation and non-coding RNAs (various miRNAs regulating TGF-β/Smad and EMT) in endometrial fibrosis, but this remains preliminary and not part of routine characterization.

Chromosomal abnormalities: Not applicable.

5. Environmental Information

• Environmental / occupational toxins: No established chemical or radiation etiology (external pelvic radiation could theoretically damage endometrium, but is not a recognized AS cause).
• Lifestyle factors: No direct causal lifestyle factors; the operative risk is procedural, not behavioral.
• Infectious agents (can trigger/cause):
• Mycobacterium tuberculosis (NCBITaxon:1773) — genital tuberculosis is a major cause of severe AS in endemic regions.
• Schistosoma spp. — genital schistosomiasis (regional).
• Polymicrobial chronic endometritis and PID organisms contribute to the inflammatory/fibrotic milieu.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Trauma to endometrial basalis (curettage, especially on gravid/postpartum uterus) → loss of the regenerative stem/progenitor niche.
2. Local ischemia and inflammation → hypoxic, pro-inflammatory microenvironment (increased macrophages, B cells, dendritic cells on single-cell profiling).
3. TGF-β1 → SMAD2/3 activation → fibroblast-to-myofibroblast transdifferentiation (↑α-SMA), with contributions from CXCR4 signaling and THBS1/PI3K-AKT (TGF-β/Smad2/3 in IUA).
4. Excessive ECM deposition — collagen I, laminin, fibronectin (FN1) from stromal fibroblasts; single-cell data show "a shift from epithelial–stromal interactions to ECM-based self-stromal signaling" (PMID:37735465).
5. Failed epithelial regeneration — dramatic epithelial loss (8.3% vs 51.65% of cells) and near-absent ciliated epithelium (0.19% vs 5.3%), with disrupted WNT (loss of WNT7A–FZD6/LRP6) and NOTCH (↓JAG1–NOTCH2) signaling impairing differentiation (PMID:37735465).
6. Anti-angiogenic environment — up-regulated IGFBP3/5/6 → poor revascularization → perpetuates ischemia (a self-reinforcing fibrotic loop).
7. Adhesion formation — opposing fibrotic walls fuse; cavity/cervical obliteration.
8. Clinical manifestation — reduced functional endometrium → hypomenorrhea/amenorrhea, impaired implantation/decidualization → infertility, RPL, placenta accreta spectrum.

Cellular processes / GO terms: - Wound healing / fibrosis: GO:0061041 (regulation of wound healing), GO:0030198 (ECM organization) - TGF-β receptor signaling: GO:0007179 - Myofibroblast differentiation / fibroblast activation - Inflammatory response: GO:0006954 - Epithelial cell differentiation: GO:0030855 (disrupted) - Angiogenesis: GO:0001525 (suppressed) - Wnt signaling: GO:0016055; Notch signaling: GO:0007219

Cell types involved (CL terms): - Endometrial stromal fibroblast → myofibroblast (CL:0000186) — the fibrogenic effector - Endometrial (luminal/glandular) epithelial cell (CL:0002586 / CL:0000066) — lost/stressed - Ciliated epithelial cell (CL:0000064) — markedly depleted - Macrophage (CL:0000235), B cell (CL:0000236), dendritic cell (CL:0000451) — expanded - Vascular endothelial cell (CL:0000115) — anti-angiogenic shift

Molecular profiling available: Single-cell RNA-seq atlas of AS endometrium (PMID:37735465; medRxiv preprint 2022) is the flagship dataset, defining the SLPI+ stressed epithelium and the pro-fibrotic/anti-angiogenic niche. This is the strongest candidate dataset for KB datasets: linkage (GEO deposition associated with the Nature Communications paper).

7. Anatomical Structures Affected

• Primary organ: Uterus (UBERON:0000995), specifically the endometrium (UBERON:0001295) and its basal layer.
• Tissue level: endometrial epithelium (glandular + luminal), endometrial stroma, uterine cavity; fibrous scar replacing functional mucosa.
• Secondary sites: cervix / cervical canal / internal os (UBERON:0000002) — obstruction here causes hematometra; fallopian tube ostia may be occluded, contributing to infertility.
• Subcellular/GO cellular component: ECM (extracellular region, GO:0005576); collagen-containing ECM (GO:0062023).
• Body system: Female reproductive system (UBERON:0000474).
• Lateralization: Adhesions are distributed within the cavity (may be marginal, central, or diffuse); disease is of a single midline organ — not lateralized per se.

8. Temporal Development

• Onset: Adult, reproductive age; acquired, temporally linked to instrumentation (days–weeks after the inciting procedure). Onset pattern is subacute (fibrosis develops over the healing window).
• Progression stages: Graded mild → moderate → severe by cavity involvement and adhesion density (see classification, §10). Severe disease features dense, cavity-obliterating adhesions and amenorrhea.
• Course: Chronic; without intervention, stable-to-progressive. Post-treatment recurrence is the defining temporal problem — reformation of adhesions after lysis, up to 62.5% in severe disease.
• Critical intervention windows: (a) Prevention window — the 2–4 week postpartum/post-miscarriage period when curettage is most dangerous; (b) Post-adhesiolysis window — early second-look hysteroscopy and barrier/estrogen measures to prevent reformation.

9. Inheritance and Population

• Inheritance: Not applicable — acquired, non-heritable. No penetrance, expressivity, anticipation, mosaicism, founder effect, consanguinity, or carrier-frequency considerations.
• Epidemiology: True population prevalence is uncertain (under-diagnosed). Procedure-conditioned incidence:
• 16–45.5% of women develop IUA after intrauterine interventions (miscarriage management, TOP, D&C) (PMID:40310333).
• Up to ~21.5% after D&C generally; up to ~40% after D&C for RPOC.
• ~1.5% of women undergoing HSG show IUA; 5–39% of women with recurrent miscarriage (Springer review).
• Orphanet lists it as a rare disease.
• Population demographics: Affects women of reproductive age worldwide; higher burden in regions with high rates of unsafe abortion, postpartum curettage, and genital tuberculosis (parts of South Asia, Africa). Sex: exclusively female (uterine organ). Mean age in cohorts ~33 years.

10. Diagnostics

Gold standard: Hysteroscopy — direct visualization of the cavity, permitting simultaneous diagnosis and treatment (Dovepress current perspectives, PMID:30936754; PMID:40310333).

Imaging / functional tests: - 3D transvaginal ultrasound (TVUS): sensitivity 98.8%, specificity 90.8%, accuracy 91.4% (PMID:40310333); useful first-line/screening; can assess endometrial thickness. - Saline infusion sonohysterography (SIS): less invasive cavity assessment. - Hysterosalpingography (HSG): shows filling defects but limited accuracy (~50%); also assesses tubal patency (PMID:40310333). - MRI: reserved for totally obliterated cavities where hysteroscopy cannot access the fundus. - Laboratory / endocrine: used to exclude other causes of amenorrhea (FSH, estradiol, prolactin, TSH, hCG) — endocrine axis is typically normal in AS, distinguishing it from ovarian/hypothalamic causes.

Classification systems: No universally validated system; ~7 exist. Most used: - American Fertility Society (AFS, 1988) scoring (extent of cavity, adhesion type, menstrual pattern) → stages I (mild), II (moderate), III (severe). - ESGE (European Society for Gynaecological Endoscopy) classification. - Nasr et al. (2000) clinicohysteroscopic score.

Differential diagnosis: Hypothalamic amenorrhea, premature ovarian insufficiency, PCOS, pregnancy, endometrial atrophy, cervical stenosis, Müllerian agenesis — distinguished by normal endocrine profile plus cavity findings on imaging/hysteroscopy.

Genetic testing: Not applicable.

11. Outcome / Prognosis

• Reproductive outcomes after hysteroscopic adhesiolysis: In a treated cohort, cumulative pregnancy rate 81.9% and cumulative live birth rate 51.2%, with outcomes stratifying by severity (low-resource setting review, PMC10848492). Milder disease has far better prognosis: AFS stage I ~>75% fertility prognosis; stage III often 25–50% (PMID:40310333).
• Recurrence: The central prognostic obstacle. Adhesion reformation correlates with baseline severity; severe IUA recurrence up to 62.5% (outcomes searches).
• Obstetric complications in achieved pregnancies: increased placenta accreta spectrum, placenta previa, preterm birth, IUGR, and miscarriage, owing to deficient decidualization over scarred segments.
• Mortality: AS is not directly life-threatening; morbidity is reproductive (infertility, pregnancy loss) and quality-of-life (chronic pain, psychological burden). Rare severe placenta accreta in subsequent pregnancy carries hemorrhage risk.
• Prognostic factors: severity/AFS stage, extent of residual functional endometrium, endometrial thickness/vascularity post-treatment, presence of chronic endometritis, and adhesion density.

12. Treatment

Standard of care — hysteroscopic adhesiolysis (NCIT:C15329 Surgical Procedure; more specifically operative hysteroscopy): - Cold microscissors preferred over electrosurgery to reduce thermal injury, perforation, and recurrence (outcomes searches). - Severe/obliterated cases may need ultrasound- or laparoscopy-guided dissection; often repeated procedures.

Post-operative adhesion-reformation prevention (adjuncts — the key strategy given high recurrence): - Physical barriers: intrauterine balloon (Foley/Cook), IUD, hyaluronic acid gel / auto–cross-linked HA (NCT02617108; HA outcomes PMID:41267665). - Hormonal (estrogen ± progestogen) therapy to stimulate re-epithelialization (NCIT:C15986 Pharmacotherapy; therapeutic_agent estrogen, CHEBI). Important recent evidence caveat: a randomized trial (Hanstede et al., 2023, PMID:37396823) found hormonal support did NOT improve recurrence, menses, or endometrial thickness — the efficacy of routine post-adhesiolysis estrogen is now questioned. Curate this as a KNOWLEDGE_GAP / competing-evidence point rather than settled benefit. - Antibiotics where chronic endometritis is present. - Platelet-rich plasma (PRP) intrauterine infusion — emerging adjunct.

Advanced / experimental (regenerative) therapeutics (NCIT:C15238 Gene Therapy / NCIT:C15431 stem-cell / cell therapy): - Menstrual blood-derived mesenchymal stem cells (MenSCs) — attenuate TGF-β, down-regulate α-SMA and collagen I, promote proliferation; act mainly via paracrine signaling (PMID:30760192; MenSC review). - Bone marrow / umbilical cord MSCs, autologous stem cell mobilization. - Stem-cell–derived exosomes and bioengineered hydrogels/scaffolds; hESC-derived endometrial organoids + 3D Matrigel (PMC8079828). - Molecular targets under study: THBS1 (PI3K/AKT), TGF-β1/Smad2/3 axis. - Assisted reproduction: IVF ± gestational surrogacy for refractory uterine-factor infertility.

Pharmacogenomics: Not applicable.

13. Prevention

• Primary prevention (most impactful):
• Avoid unnecessary curettage; prefer medical management (misoprostol) or expectant management for miscarriage.
• Use ultrasound-guided gentle suction / manual vacuum aspiration rather than sharp curettage.
• Avoid the 2–4 week postpartum/post-miscarriage high-risk window for instrumentation (Fertility & Sterility; PMID:33462894).
• Limit repeat intrauterine procedures; treat genital infections (including TB) promptly.
• Secondary prevention: early hysteroscopic diagnosis in women with post-procedure menstrual change or infertility; treat chronic endometritis.
• Tertiary prevention: post-adhesiolysis barriers (balloon/HA gel), early second-look hysteroscopy to lyse re-forming adhesions, and endometrial-regeneration adjuncts.
• Counseling: reproductive/pre-conception counseling; genetic counseling not applicable.

14. Other Species / Natural Disease

• Taxonomy: Human disease (Homo sapiens, NCBITaxon:9606). Naturally occurring analogous intrauterine adhesion disease in other species is not well documented; endometrial fibrosis/scarring can occur in domestic animals but "Asherman syndrome" is a human clinical entity.
• Breed / OMIA / veterinary: No established OMIA entry (acquired, not genetic).
• Comparative biology: Endometrial regeneration is a conserved mammalian process; rodents serve as mechanistic surrogates rather than natural-disease models.
• Zoonosis / transmission: Not applicable.

15. Model Organisms

• Rodent (mouse/rat) mechanical/chemical injury models — the workhorse: Induced by intrauterine curettage/scraping, electrocoagulation, ethanol/trichloroacetic-acid instillation, or dual mechanical+LPS injury. These recapitulate endometrial fibrosis, ↑TGF-β1/Smad, ↑α-SMA/collagen, thinned endometrium, and impaired fertility, and are the standard platform for testing MSC/exosome/hydrogel therapies (mechanisms & stem cell therapy review).
• In vitro / cellular models: primary human endometrial stromal cells with TGF-β1 stimulation (fibrosis induction); endometrial epithelial cultures; iPSC/hESC-derived endometrial organoids (PMC8079828).
• Model characteristics / limitations: Rodent uterine anatomy (bicornuate, rapid estrous cycling, high regenerative capacity) differs from human; models capture fibrosis and functional infertility well but imperfectly reproduce the human implantation-window epithelial phenotype and chronic recurrence dynamics. evidence_source: MODEL_ORGANISM for all rodent data; IN_VITRO for organoid/cell work.
• Resources: No dedicated AS model repository; models are protocol-defined and reported ad hoc in the literature.

Key Ontology Term Summary (for KB population)

• MONDO: MONDO:0015299 (Asherman syndrome)
• Phenotypes (HP): HP:0000141 (Amenorrhea), HP:0011225 (Hypomenorrhea), HP:0008222 (Female infertility), HP:0500110/HP:0100615 (Recurrent spontaneous abortion), HP:0030144 (Hematometra), HP:0031331 (Abnormal uterine morphology)
• Anatomy (UBERON): UBERON:0001295 (endometrium), UBERON:0000995 (uterus), UBERON:0000002 (cervix), UBERON:0000474 (female reproductive system)
• Cells (CL): CL:0000186 (myofibroblast), CL:0000066 (epithelial cell), CL:0000064 (ciliated cell), CL:0000235 (macrophage)
• Processes (GO): GO:0007179 (TGF-β receptor signaling), GO:0030198 (ECM organization), GO:0061041 (regulation of wound healing), GO:0001525 (angiogenesis), GO:0016055 (Wnt signaling)
• Treatments (NCIT): NCIT:C15329 (Surgical Procedure — hysteroscopic adhesiolysis), NCIT:C15986 (Pharmacotherapy — estrogen), NCIT:C15238 (Gene Therapy), cell therapy (MSC)

Curation Caveats / Evidence Notes

1. Acquired disease — do not populate causal-gene, inheritance, or germline-variant slots; explicitly mark N/A.
2. Hormonal support efficacy is contested — the 2023 RCT (PMID:37396823) is a REFUTE/PARTIAL-type evidence item against routine post-op estrogen; curate as a knowledge gap.
3. Single-cell atlas (PMID:37735465) is the strongest molecular source for pathophysiology nodes and has an associated GEO dataset worth linking.
4. Verify all PMIDs and snippets with just fetch-reference before committing — PubMed abstracts were partly cookie-walled during this research; the exact-quote SOP (§Adding Evidence) must be applied to each claim.
5. This entry is a strong candidate to conforms_to the fibrotic_response module (tissue injury → inflammation → myofibroblast activation → excessive ECM → organ dysfunction), substituting endometrial stromal fibroblast → myofibroblast.

Sources

• Decoding the endometrial niche of Asherman's Syndrome at single-cell resolution — Nat Commun, PMID:37735465 (PMC10514053)
• Intrauterine Adhesions and Asherman Syndrome: Retrospective Dive into Risk Factors, Diagnosis, Surgical Perspectives — PMID:40310333 (PMC12026105)
• Identifying risk factors and incidence of Asherman Syndrome in post-abortion curettage — PMID:33462894
• Mechanistic insights into intrauterine adhesions — PMID:39613882
• Asherman's syndrome: current perspectives on diagnosis and management — PMID:30936754 (Dovepress)
• The management of Asherman syndrome: a review of literature — Reprod Biol Endocrinol (Springer)
• Hormonal support in women with Asherman syndrome does not lead to better outcomes: a randomized trial — PMID:37396823 (PMC10308500)
• Novel therapeutic strategies: endometrial regeneration using menstrual blood-derived stem cells — ScienceDirect
• Endometrial Regeneration in Asherman's Syndrome: stem cell therapies — PMID:30760192
• Stem cell therapy targets THBS1 to reverse endometrial fibrosis — Frontiers (PMC12916671)
• Endometrial membrane organoids from hESC + 3D Matrigel — PMC8079828
• Review of Asherman syndrome and hysteroscopic treatment outcomes (low-resource setting) — PMC10848492
• Fertility & obstetric outcomes: hyaluronic acid post-adhesiolysis — PMID:41267665
• Avoiding Asherman's syndrome: refining uterine evacuation — Fertility and Sterility
• Intrauterine balloon + postoperative estrogen — NCT02617108
• NORD — Asherman's Syndrome
• Orphanet — Asherman syndrome (ORPHA:137686)
• Mechanisms of Endometrial Fibrosis and Stem Cell Therapy — Discovery Medicine

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.